drugset / Press release
Novo Nordisk A/S: FDA berammer møde i rådgivende komite om insulin degludec og insulin degludec/insulin aspart
2012-07-18 · Novo Nordisk A/S · original novonordisk.com ↗
Degludec
Insulin · regulatory
Insulin degludec/insulin aspart
Insulin degludec/insulin aspart
insulin aspart
insulin degludec
insulin degludec/insulin aspart · regulatory
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart · regulatory
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart · regulatory
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart · regulatory
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
regular insulin
Novo Nordisk meddelte i dag, at de amerikanske sundhedsmyndigheder, FDA, har oplyst, at man vil afholde et møde i FDA's rådgivende komite, hvor registreringsansøgningerne for ultralangtidsvirkende insulin degludec og insulin degludec/insulin aspart vil blive drøftet. Mødet er foreløbigt planlagt til at blive afholdt den 8. november 2012. Yderligere information: Medier: Investorer: Mike Rulis Kasper Roseeuw Poulsen Tlf. 3079 3573 Tlf. 4442 4303 [email protected] [email protected] Frank Daniel Mersebach Tlf. 4442 0604 [email protected] Lars Borup Jacobsen Tlf. 3075 3479 [email protected] Selskabsmeddelelse nr. 46 / 2012
The release as fetched from its publisher. novonordisk.com ↗